SpectraCure AB (publ) OMXSTO:SPEC:
STUDY SHOWS SIGNIFICANT PSA REDUCTION IN PROSTATE CANCER PATIENTS
PSA LEVELS DROP TO 0.0-0.5 NG/ML AFTER TREATMENT
Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
On 6ix: 6ix.com/news/spectracure-says-study-shows-significant-psa-reduction-in-prostate-cancer-patients
Earlier from SpectraCure
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Gets Approval To Commence Clinical Trial
- Spectracure Appoints Johannes Swartling As CEO
- Spectracure Reports Positive Results In Prostate Cancer Study
Later from SpectraCure
- Spectracure Q3 Net Loss SEK 35 Mln
- Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
- Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
- SPEC: Promising clinical progress, but widened losses and liquidity risks raise going concern doubts
- Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure